Retinoblastoma is the most common malignant eye tumor in children, accounting for approximately 3% of pediatric tumors. It affects one or both eyes in the first years of life. It originates in the cells of the retina.
In developed countries, including Portugal, the overall survival rate is 95%.
In recent years, there has been great progress in its treatment, with improved preservation of the eyeball and vision, to which early diagnosis also contributes.
There are several signs and symptoms present in the diagnosis of retinoblastoma.
These children are usually in good general health and do not appear to be ill.
Should be investigated given the following signs/symptoms:
Although it is a cancer with a high survival rate, most of these children live with the consequences of a late diagnosis, with the loss of one or both eyes and consequent use of an ocular prosthesis, decreased vision, or even total blindness. About 60-70% of cases with Retinoblastoma diagnosed late require enucleation (complete removal of the eyeball).
It is vital that doctors, particularly Pediatricians and General Practitioners, know the warning signs, such as checking the Red Reflex, so that they can refer urgently whenever necessary.
More than 80% of patients are diagnosed late, and all of them after suspicion raised by parents or other family members.
Retinoblastoma is hereditary in about 40% of cases, and every child carrying the Rb gene has about a 90% risk of developing the disease. In these cases, screening should be performed from birth at the National Reference Center for Onco-Ophthalmology.
Observation in Genetic consultation of familial Retinoblastoma cases is mandatory for conducting genetic studies and counseling. Preimplantation and prenatal genetic testing (chorionic villus sampling and amniocentesis) is possible in cases of couples where one partner carries the Rb gene.
For more information, please contact:: oftalmologia@chuc.min-saude.pt
Acreditar’s work is only possible with your support.
Thank you very much for helping improve the quality of life of children and young people with cancer!
Ao subscrever está a aceitar a Política de Privacidade da Acreditar. Damos muito valor à sua privacidade e por isso garantimos a confidencialidade dos seus dados.